Sertoli cell therapy: A novel possible treatment strategy for treatment-resistant major depressive disorder

Medical Hypotheses

Volumn 77, Issue 1, 2011, Pages 35-42

  Loftis, J M ^a,b  

^a PORTLAND VA MEDICAL CENTER   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; MYELIN;

ARTICLE; CELL THERAPY; CELL TRANSPLANTATION; HUMAN; IMMUNOREGULATION; MAJOR DEPRESSION; NERVE CELL PLASTICITY; NERVOUS SYSTEM DEVELOPMENT; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; SERTOLI CELL; STEM CELL TRANSPLANTATION;

CYTOKINES; DEPRESSIVE DISORDER, MAJOR; HUMANS; MALE; OXIDATIVE STRESS; SERTOLI CELLS; TISSUE THERAPY;

EID: 79958047244     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2011.03.017     Document Type: Article

References (151)

1. Kessler R.C., Berglund P., Demler O., et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003, 289(23):3095-3105.
2. Kruijshaar M.E., Hoeymans N., Spijker J., Stouthard M.E., Essink-Bot M.L. Has the burden of depression been overestimated?. Bull World Health Organ 2005, 83(6):443-448.
3. Murray C.J., Lopez A.D. Evidence-based health policy, lessons from the Global Burden of Disease Study. Science 1996, 274(5288):740-743.
4. "Depression out of the shadows." PBS. OPB/OREGON PUBLIC BROADCASTING CHANNEL 10, Portland; May 21, 2008.
5. Trivedi M.H., Rush J., Wisnieswski S.R., et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 2006, 163:28-40.
6. Judd L.L., Akiskal H.S., Zeller P.J., et al. Psychosocial disability during the long-term course of unipolar major depressive disorder. Arch Gen Psychiatry 2000, 57:375-380.
7. Judd L.L., Paulus M.J., Schettler P.J., et al. Does incomplete recovery from first lifetime major depressive episode herald a chronic course of illness?. Am J Psychiatry 2000, 157:1501-1504.
8. Kurian B.T., Greer T.L., Trivedi M.H. Strategies to enhance the therapeutic efficacy of antidepressants: targeting residual symptoms. Expert Rev Neurother 2009, 9(7):975-984.
9. Hendrie C.A., Sarailly J., Starkey N.J. Evidence to suggest that selfmedication with alcohol is not an effective treatment for the control of depression. Psychopharmacology 1998, 12:112.
10. Hendrie C.A., Pickles A.R. Depression as an evolutionary adaptation: anatomical organisation around the third ventricle. Med Hypotheses 2010, 74(4):735-740.
11. Lacasse J.R., Leo J. Seratonin and depression: a disconnect between the advertisements and the scientific literature. PLoS Med 2005, 2(12):e392.
12. Moncrieff J. Are antidepressants as effective as claimed? No, they are not effective at all. Can J Psychiatry 2007, 52(11):750.
13. American Psychiatric Association. The Diagnostic and Statistical Manual of Mental Disorders (DSM). DSM-IV-TR; 2000.
14. Little A. Treatment-resistant depression. Am Fam Physician 2009, 80(2):167-172.
15. Fitzgerald P.B., Daskalakis Z.J. The use of repetitive transcranial magnetic stimulation and vagal nerve stimulation in the treatment of depression. Curr Opin Psychiatry 2008, 21(1):25-29.
16. Martinez-Amoros E., Barrero E.R., Fusares C.F., Hernandez-Ribas R., Sarachaga M.U. Bilateral posterior vitreous detachment after electroconvulsive therapy. Gen Hosp Psychiatry 2009, 31(4):385-387.
17. Lee H.M., Lim H.G., Oh B.C., Park C.S., Lee D.S., Lee J.R. Systemic immune modulation using chemokine receptor 7 expressing porcine Sertoli cells. Xenotransplantation 2007, 14(6):619-626.
18. Loftis J.M., Huckans M., Morasco B.J. Neuroimmune mechanisms of cytokine-induced depression: current theories and novel treatment strategies. Neurobiol Disease 2010, 37(3):519-533.
19. Maes M. Depression is an inflammatory disease, but cell-mediated immune activation is the key component of depression. Prog Neuropsychopharmacol Biol Psychiatry 2010, 1:12.
20. Pace T.W.W., Miller A.H. Cytokines and glucocorticoid receptor signaling. Ann NY Acad Sci 2009, 1179:86-105.
21. Olfson M., Marcus S.C., Druss B., Elinson L., Tanielian T., Pincus H.A. National trends in the outpatient treatment of depression. JAMA 2002, 287(2):203-209.
22. Turner E.H., Matthews A.M., Linardatos E., Tell R.A., Rosenthal R. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med 2008, 358:252-260.
23. Demyttenaere K., Jaspers L. Bupropion and SSRI-induced side effects. J Psychopharmacol 2008, 22(7):792-804.
24. Tiihonen J., Lönnqvist J., Wahlbeck K., Klaukka T., Tanskanen A., Haukka J. Antidepressants and the risk of suicide, attempted suicide, and overall mortality in a nationwide cohort. Arch Gen Psychiatry 2006, 63(12):1358-1367.
25. Rubino A., Roskell N., Tennis P., Mines D., Weich S., Andrews E. Risk of suicide during treatment with venlafaxine, citalopram, fluoxetine, and dothiepin: retrospective cohort study. BMJ 2007, 334(7587):242.
26. Capuron L., Gumnick J.F., Musselman D.L., et al. Neurobehavioral effects of interferon-A in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacology 2002, 26(5):643-652.
27. Loftis J.M., Huckans M., Ruimy S., Hinrichs D.J., Hauser P. Depressive symptoms in patients with chronic hepatitis C are correlated with elevated plasma levels of interleukin-1β and tumor necrosis factor-α. Neurosci Lett 2008, 430(3):264-268.
28. Koo J.W., Duman R.S. IL-1β is an essential mediator of the antineurogenic and anhedonic effects of stress. PNAS 2008, 105(2):751-756.
29. Stockmeier C.A., Mahajan G.J., Konick L.C., et al. Cellular changes in the postmortem hippocampus in major depression. Biol Psychiatry 2004, 56(9):640-650.
30. Duman R.S., Monteggia L.M. A neurotrophic model for stress-related mood disorders. Biol Psychiatry 2006, 59(12):1116-1127.
31. Fuchs E., Czeh B., Kole M.H., Michaelis T., Lucassen P.J. Alterations of neuroplasticity in depression: the hippocampus and beyond. Eur Neuropsychopharmacol 2004, 14(S5):S481-S490.
32. Maes M., Bosmans E., De Jongh R., Kenis G., Vandoolaeghe E., Neels H. Increased serum IL-6 and IL-1 receptor antagonist concentrations in major depression and treatment resistant depression. Cytokine 1997, 9:853-858.
33. O'Brien S.M., Scully P., Fitzgeral P., Scott L.V., Dinan T.G. Plasma cytokine profiles in depressed patients who fail to respond to selective serotonin reuptake inhibitor therapy. J Psychiatry Res 2007, 41:326-331.
34. Eller T., Vasar V., Slik J., Maron E. Pro-inflammatory cytokines and treatment response to escitaloprsam in major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32(2):445-450.
35. Tfilin M, Sudai E, Merenlender A, Gispan I, Yadid G, Turgeman G. Mesenchymal stem cells increase hippocampal neurogenesis and counteract depressive-like behavior. Mol Psychiatry; 2009 [advanced online publication].
36. Murray F.T., Beyer-Mears A., Johnson R.D., et al. Assessment of proteinuria and neuropathy in the nonimmunosuppressed Bb diabetic rat after abdominal intratesticular islet transplantation. Transplantation 1993, 56(3):680-686.
37. Dufour J.M., Rajotte R.V., Seeberger K., Kin T., Korbutt G.S. Long-term survival of neonatal porcine Sertoli cells in non-immunosuppressed rats. Xenotransplantation 2003, 10(6):577-586.
38. Yin Z., Chen D., Hu F., et al. Cotransplantation with xenogenetic neonatal porcine Sertoli cells significantly prolongs islet allograft survival in immunosuppressive rats. Transplantation 2009, 88(3):339-345.
39. Sanberg P.R., Willing A.E., Cahill D.W. Novel cellular approaches to repair of neurodegenerative disease: from Sertoli cells to umbilical cord blood stem cells. Neurotox Res 2002, 4(2):95-101.
40. Lewitus G.M., Wilf-Yarkoni A., Ziv Y. Vaccination as a novel approach for treating depressive behavior. Biol Psychiatry 2009, 65(4):283-288.
41. Griswold M.D. The central role of Sertoli cells in spermatogenesis. Semin Cell Dev Biol 1998, 9:411-416.
42. Guazzone V.A., Jacobo P., Theas M.S., Lustig L. Cytokines and chemokines in testicular inflammation: a brief review. Microsc Res Tech 2009, 72(8):620-628.
43. Mital P., Kaur G., Dufour J.M. Immunoprotective Sertoli cells: making allogeneic and xenogeneic transplantation feasible. Reproduction 2010, 139:495-504.
44. Palmero S., Bardi G., Coniglio L., Falugi C. Presence and localization of molecules related to the cholinergic system in developing rat testis. Eur J Histochem 1999, 43(4):277-283.
45. Mayerhofer A., Frungieri M.B., Fritz S., Bulling A., Jessberger B., Vogt H.J. Evidence for catecholaminergic neuronlike cells in the adult human testis: changes associated with testicular pathologies. J Androl 1999, 20(3):341-347.
46. Pitychoutis P.M., Nakamura K., Tsonis P.A., Papadopoulou-Daifoti Z. Neurochemical and behavioral alterations in an inflammatory model of depression: sex differences exposed. Neuroscience 1999, 159:1216-1232.
47. Konsman J.P., Veeneman J., Combe C., Poole S., Luheshi G.N., Dantzer R. Central nervous action of interleukin-1 mediates activation of limbic structures and behavioural depression in response to peripheral administration of bacterial lipopolysaccharide. Eur J Neurosci 2008, 28:2499-2510.
48. O'Bryan M.K., Gerdprasert O., Nikolic-Paterson D.J., et al. Cytokine profiles in the testes of rats treated with lipopolysaccharide reveal localized suppression of inflammatory responses. Am J Physiol Reg Int Comp Physiol 2005, 288(6):R1744-R1755.
49. Shamekh R., Mallery J., Newcomb J., et al. Enhancing tyrosine hydroxylase expression and survival of fetal ventral mesencephalon neurons with rat or porcine Sertoli cells in vitro. Brain Res 2006, 1096:1-10.
50. Korbutt G.S., Elliott J.F., Rajotte R.V. Cotransplantation of allogeic islets with allogeneic testicular cell aggregates allows long-term graft survival without systemic immunosuppression. Diabetes 1997, 46(2):317-322.
51. Sanberg P.R., Borlongan C.V., Saporta S., Cameron D.F. Testis-derived Sertoli cells survive and provide localized immunoprotection for xenografts in rat brain. Nat Biotechnol 1996, 14:1692-1695.
52. Suarez-Pinzon W., Korbutt G.S., Power R., Hooton J., Rajotte R.V., Rabinovitch A. Testicular Sertoli cells protect islet beta-cells from autoimmune destructions in NOD mice by a transforming growth factor-beta1-dependent mechanism. Diabetes 2000, 49(11):1810-1818.
53. Yang H., Al-Jazaeri A., Wright J.R. The immunoprotective effect of Sertoli cells coencapsulated with islet xenografts is not dependent up on Fas ligand expression. Cell Transplant 2002, 11(8):799-801.
54. Willing A.E., Othberg A.I., Saporta S., et al. Sertoli cells enhance the survival of co-transplanted dopamine neurons. Brain Res Bull 1999, 822(1-2):246-250.
55. Shamekh R., Saporta S., Cameron D.F., et al. Effects of Sertoli cell-conditioned medium on ventral midbrain neural stem cells: a preliminary report. Neurotox Res 2008, 13(3-4):241-246.
56. Hemendinger R., Wang J., Malik S., et al. Sertoli cells improve survival of motor neurons in SOD1 transgenic mice, a model of amyotrophic lateral sclerosis. Exp Neurol 2005, 196(2):235-243.
57. Dufour J.M., Dass B., Halley K.R., Korbutt G.S., Dixon D.E., Rajotte R.V. Sertoli cell line lacks the immunoprotective properties associated with primary Sertoli cells. Cell Transplant 2008, 17(5):525-534.
58. Sanberg P.R., Borlongan C.V., Othberg A.I., Saporta S., Freeman T.B., Cameron D.F. Testis-derived Sertoli cells have a trophic effect on dopamine neurons and alleviate hemiparkinsonism in rats. Nat Med 1997, 3(10):1129-1132.
59. Borlongan C.V., Cameron D.F., Saporta S., Sanberg P.R. Intracerebral transplantation of testic-derived Sertoli cells promotes functional recovery in female rats with 6-hydrocydopamine-induced hemiparkinsonism. Exp Neurol 1997, 148(1):388-392.
60. Emerich D.F., Hemendinger R., Halberstadt C.R. Review: the testicular-derived Sertoli cell: cellular immunoscience to enable transplantation. Cell Transplant 2003, 12(4):335-349.
61. Fallarino F., Luca G., Calvitti M., et al. Therapy of experimental type 1 diabetes by isolated Sertoli cell xenografts alone. J Cell Biol 2009, 206(11):2511-2526.
62. Miller A.H. Norman Cousins Lecture. Mechanisms of cytokine-induced behavioral changes: psychoneuroimmunology at the translational interface. Brain Behav Immun 2009, 23(2):149-158.
63. Maes M., Yirmyia R., Noraberg J., et al. The inflammatory & neurodegenerative (I&ND) hypothesis of depression: leads for future research and new drug developments in depression. Metab Brain Dis 2009, 24(1):27-53.
64. Dantzer R. Cytokine, sickness behavior, and depression. Immunol Allergy Clin North Am 2009, 29(2):247-264.
65. Harrison N.A., Brydon L., Walker C., et al. Neural origins of human sickness in interoceptive responses to inflammation. Biol Psychiatry 2009, 66(5):415-422.
66. Piser T.M. Linking the cytokine and neurocircuitry hypotheses of depression: a translational framework for discovery and development of novel anti-depressants. Brain Behavior Immun 2010, 24(4):515-524.
67. McNally L., Bhagwagarm Z., Hannestad J. Inflammation, glutamate, and glia in depression: a literature review. CNS Spectrums 2008, 13(6):501-510.
68. Boka G., Anglade P., Wallach D., Javoy-Agid F., Agid Y., Hirsch E.C. Immunocytochemical analysis of tumor necrosis factor and its receptors in Parkinson's disease. Neurosci Lett 1994, 172(1-2):151-154.
69. Khairova R.A., Machado-Vieira R., Du J., Manji H.K. A potential role for pro-inflammatory cytokines in regulation synaptic plasticity in major depressive disorder. Int J Neuropsychopharmacol 2009, 561:578.
70. Parnet P., Amindari S., Wu C., et al. Expression of type I and type II interleukin-1 receptors in mouse brain. Mol Brain Res 1994, 27(1):63-70.
71. Schobitz B., de Kloet E.R., Sutanto W., Holsboer F. Cellular localization of interleukin 6 mRNA and interleukin 6 receptor mRNA in rat brain. Eur J Neurosci 1993, 5(11):1426-1435.
72. Maes M., Scharpe S., Meltzer H.Y., et al. Relationships between interleukin-6 activity, acute phase proteins, and function of the hypothalamic-pituitary-adrenal axis in severe depression. Psychiatry Res 1993, 49(1):11-27.
73. Anisman H., Kokkinidis L., Merali Z. Further evidence for the depressive effects of cytokines: anhedonia and neurochemical changes. Brain Behav Immun 2002, 16(5):544-556.
74. Bonaccorso S., Marino V., Puzella A., et al. Increased depressive ratings in patients with hepatitis C receiving interferon-alpha-based immunotherapy are related to interferon-alpha-induced changes in the serotonergic system. J Clin Psychopharmacol 2002, 22(1):86-90.
75. Capuron L., Ravaud A., Neveu P.J., Miller A.H., Maes M., Dantzer R. Association between decreased serum tryptophan concentrations and depressive symptoms in cancer patients undergoing cytokine therapy. Mol Psychiatry 2002, 7(5):468-473.
76. McAfoose J., Baune B.T. Evidence for a cytokine model of cognitive function. Neurosci Biobehav Rev 2009, 33(3):355-366.
77. Butler M.P., O'Connor J.J., Moynagh P.N. Dissection of tumor-necrosis factor-alpha inhibition of long-term potentiation (LTP) reveals a p38 mitogen-activated protein kinase-dependent mechanism which maps to early-but not late-phase LTP. Neuroscience 2004, 124(2):319-326.
78. Cunningham A.J., Murray C.A., O'Neill L.A., Lynch M.A., O'Connor J.J. Interleukin-1 beta (IL-1 beta) and tumour necrosis factor (TNF) inhibit long-term potentiation in the rat dentate gyrus in vitro. Neurosci Lett 1996, 203(1):17-20.
79. Sarandol A., Sarandol E., Eker S.S., Erdinc S., Vatansever E., Kirli S. Major depressive disorder is accompanied with oxidative stress: short-term antidepressant treatment does not alter oxidative-antioxidative systems. Hum Psychopharmacol 2007, 22(2):67-73.
80. Shelton RC, Claiborne J, Sidoryk-Wergrzynowicz M, et al. Altered expression of genes involved in inflammation and apoptosis in frontal cortex in major depression. Mol Psychiatry; 2010 [Epub ahead of print].
81. Michel T.M., Camara S., Tatschner T., et al. Increased xanthine oxidase in the thalamus and putamen in depression. World J Biol Psychiatry 2010, 11(2):314-320.
82. Neurauter G., Schrocksnadel K., Scholl-Burgi S., et al. Chronicimmune stimulation correlates with reduced phenylalanine turnover. Curr Drug Metab 2008, 9(7):622-627.
83. Srivastava N., Barthwal M.K., Dalal P.K., et al. A study on nitric oxide, beta-adrenergic receptors and antioxidant status in the polymorphonuclear leukocytes from the patients of depression. J Affect Disord 2002, 72:45-52.
84. Harvey B.H. Affective disorders and nitric oxide: a role in pathways to relapse and refractoriness. Hum Psychopharmacol Clin Exp 1996, 11:309-311.
85. Bernstein H.G., Heinemann A., Krell D., et al. Further immunohistochemical evidence for impaired NO signaling in the hypothalamus of depressed patients. Ann NY Acad Sci 2002, 973:91-93.
86. Elgun S., Kumbasar H. Increased serum arginase activity in depressed patients. Prog Neuropsychopharmacol Biol Psychiatry 2000, 24:227-232.
87. Selek S., Savas H.A., Gergerlioglu H.S., Bulbul F., Uz E., Yumru M. The course of nitric oxide and superoxide dismutase during treatment of bipolar depressive episode. J Affect Disord 2008, 107(1-3):89-94.
88. Chrapko W., Jurasz P., Radomski M.W., et al. Alteration of decreased plasma NO metabolites and platelet NO synthase activity by paroxetine in depressed patients. Neuropsychopharmacology 2005, 31:1286-1293.
89. Kumar A., Garg R., Gaur V., Kumar P. Venlafaxine involves nitric oxide modulatory mechanism in experimental model of chronic behavior despair in mice. Brain Res 2010, 1311:73-80.
90. Ishikawa T., Morris P.L. Interleukin-1B signals through a c-Jun N-terminal kinase-dependent inducible nitric oxide synthase and nitric oxide production pathway in Sertoli epithelial cells. Endocrinology 2006, 147(11):5424-5430.
91. Wyatt C.R., Law L., Magnuson J.A., Griswold M.D., Magnuson N.S. Suppression of lymphocyte proliferation by proteins secreted by cultured Sertoli cells. J Reprod Immunol 1988, 14(1):27-40.
92. Selawry H.P., Kotb M., Herrod H.G., Lu Z. Production of a factor, or factors, suppressing IL-2 production and T cell proliferation by Sertoli cell-enriched preparations: a potential role for islet transplantation in an immunologically privileged site. Transplantation 1991, 52(5):846-850.
93. De Cesaris P., Filippini A., Cervelli C., et al. Immunosuppressive molecules produced by Sertoli cells cultured in vitro: biological effects on lymphocytes. Biochem Biophys Res Commun 1992, 186(3):1639-1646.
94. Fields R.D. White matter in learning, cognition and psychiatric disorders. Trends Neurosci 2008, 31(7):361-370.
95. Feng Y. Convergence and divergence in the etiology of myelin impairment in psychiatric disorders and drug addiction. Neurochem Res 2008, 33(10):1940-1949.
96. Gunning-Dixon F.M., Hoptman M.J., Lim K.O., et al. Macromolecular white matter abnormalities in geriatric depression: a magnetization transfer imaging study. Am J Geriatr Psychiatry 2008, 16(4):255-262.
97. Lenze E., Cross D., McKeel D., Neuman R.J., Sheline Y.I. White matter hyperintensities and gray matter lesions in physically healthy depressed subjects. Am J Psychiatry 1999, 156:1602-1607.
98. Uranova N., Orlovskaya D., Vikhreva O., et al. Electron microscopy of oligodendroglia in severe mental illness. Brain Res Bull 2001, 55(5):597-610.
99. Uranova N.A., Vostrikov V.M., Orlovskaya D.D., Rachmanova V.I. Oligodendroglial density in the prefrontal cortex in schizophrenia and mood disorders: a study from the Stanley Neuropathology Consortium. Schizophr Res 2004, 67(2-3):269-275.
100. Regenold W.T., Phatak P., Marano C.M., Gearhart L., Viens C.H., Hisley K.C. Myelin staining of deep white matter in the dorsolateral prefrontal cortex in schizophrenia, bipolar disorder, and unipolar major depression. Psychiatry Res 2007, 151(3):179-188.
101. Pang Z.P., Cao P., Xu W., Sudhof T.C. Calmodulin controls synaptic strength via presynaptic activation of calmodulin kinase II. Neuroscience 2010, 30(11):4132-4142.
102. Steiner J., Bielau H., Brisch R., et al. Immunological aspects in the neurobiology of suicide: elevated microglial density in schizophrenia and depression is associated with suicide. J Psychiatry Res 2008, 42(2):151-157.
103. Schmitz T., Chew L.J. Cytokines and myelination in the central nervous system. ScientificWorldJournal 2008, 2(8):1119-1147.
104. Block M.L., Zecca L., Hong J.S. Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat Rev Neurosci 2007, 8:57-69.
105. Qin L., Block M.L., Liu Y., et al. Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration. Glia 2007, 55(5):453-462.
106. Lyng K., Munkeby B.H., Saugstad O.D., Stray-Pedersen B., Froen J.F. Effect of interleukin-10 on newborn piglet brain following hypoxia-ischemia and endotoxin-induced inflammation. Biol Neonate 2005, 87:207-216.
107. Gow A., Southwood C.M., Li J.S., et al. CNS myelin and Sertoli cell tight junction strands are absent in Osp/claudin-11 null mice. Cell 1999, 99(6):649-659.
108. Duman R.S., Malberg J., Thome J. Neural plasticity to stress and antidepressant treatment. Biol Psychiatry 1999, 46:1181-1191.
109. Kempermann G., Krebs J., Fabel K. The contribution of failing adult hippocampal neurogenesis to psychiatric disorders. Curr Opin Psychiatry 2008, 21(3):290-295.
110. Czeh B., Michaelis T., Watanabe T., et al. Stress-induced changed in cerebral metabolise, hippocampal volume, and cell proliferation are prevented by antidepressant treatment with tianeptine. PNAS 2001, 98(22):12796-12801.
111. Xu H., Luo C., Richardson J.S., Li X.M. Recovery of hippocampal cell proliferation and BDNF levels, both of which are reduced by repeated restraint stress, is accelerated by chronic venlafaxine. Pharmacogenomics 2004, 4:322-331.
112. Santarelli L., Saxe M., Gross C., et al. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 2003, 301(5634):805-809.
113. Malberg J.E., Eisch A.J., Nestler E.J., Duman R.S. Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. J Neurosci 2000, 20(24):9104-9110.
114. Bremner J.D., Narayan M., Anderson E.R., Staib L.H., Miller H.L., Charney D.S. Hippocampal volume reduction in major depression. Am J Psychiatry 2000, 157:115-118.
115. Frodl T., Meisenzahl E.M., Zetzsche T., et al. Hippocampal changes in patients with a first episode of major depression. Am J Psychiatry 2002, 159:1112-1118.
116. MacQueen G.M., Campbell S., McEwen B.S., et al. Course of illness, hippocampal function, and hippocampal volume in major depression. PNAS 2003, 100(3):1387-1392.
117. Mervaala E., Fohr J., Kononen M., et al. Quantitative MRI of the hippocampus and amygdale in severe depression. Psychol Med 2000, 30(1):117-125.
118. Shah P.J., Ebmeier K.P., Glabus M.F., Goodwin G.M. Cortical grey matter reductions associated with treatment-resistant chronic unipolar depression. Controlled magnetic resonance imaging study. Br J Psychiatry 1998, 172:527-532.
119. Sheline Y.I., Wang P.W., Gado M.H., Csernansky J.G., Vannier M.W. Hippocampal atrophy in recurrent major depression. PNAS 1996, 93(9):3908-3913.
120. Sheline Y.I., Sanghavi M., Mintun M.A., Gado M.H. Depression duration but not age predicts hippocampal volume loss in medically healthy women with recurrent major depression. J Neurosci 1999, 19(12):5034-5043.
121. Steffens D.C., Byrum C.E., McQuoid D.R., et al. Hippocampal volume in geriatric depression. Biol Psychiatry 2000, 48(4):301-309.
122. Campbell S., Marriott M., Nahmias C., MacQueen G.M. Lower hippocampal volume in patients suffering from depression: a meta-analysis. Am J Psychiatry 2004, 161:598-607.
123. Rosoklija G., Toomayan G., Ellis S.P., et al. Structural abnormalities of subicular dendrites in subjects with schizophrenia and mood disorders. Arch Gen Psychiatry 2000, 57(4):349-356.
124. Michael-Titus A.T., Albert M., Michael G.J., et al. SONU20176289, a compound combining partial dopamine D2 receptor agonism with specific serotonin reuptake inhibitor activity, affects neuroplasticity in an animal model for depression. Eur J Pharmacol 2008, 598(1-3):43-50.
125. Fujioka T., Fujioka A., Duman R.S. Activation of cAMP signaling facilitates the morphological maturation of newborn neurons in adult hippocampus. J Neurosci 2004, 24(2):319-328.
126. Mathieu P., Piantanida A.P., Pitossi F. Chronic expression of transforming growth factor-veta enhances adult neurogenesis. Neuroimmunomodulation 2010, 17:200-201.
127. Chen J.J., Sun Y., Nabel G.J. Regulation of the proinflammatory effects of Fas ligand (CD95L). Science 1998, 282(5394):1714-1717.
128. Cao D., Kevala K., Kim J., et al. Docosahexaenoic acid promotes hippocampal neuronal development and synaptic function. J Neurochem 2009, 111(2):510-521.
129. Yoo S., Liu J., Sabbadini M., Au P., Xie G.X., Yost S. Regional expression of the anesthetic-activated potassium channel TRESK in the rat nervous system. Neurosci Lett 2009, 465(1):79-84.
130. Lim C.M., Kim S.W., Park J.Y., et al. Fluoxetine affords robust neuroprotection in the postischemic brain via its anti-inflammatory effect. J Neurosci Res 2009, 87(4):1037-1045.
131. Bengtsson B.O., Zhu J., Thorell L.H., Olsson T., Link H., Walinder J. Effects of zimelidine and its metabolites, clomipramine, imipramine and maprotiline in experimental allergic neuritis in Lewis rats. J Neuroimmunol 1992, 39:109-122.
132. Zhu J., Bengtsson B.O., Mix E., et al. Clomipramine and imipramine suppress clinical signs and T and B cell response to myelin proteins in experimental autoimmune neuritis in Lewis rats. J Autoimmun 1998, 11:319-327.
133. Kubera M., Simbirtsev A., Mathison R., Maes M. Effects of repeated fluoxetine and citalopram administration on cytokine release in C57BL/6 mice. Psychiatry Res 2000, 96:255-266.
134. Hashioka S., Klegeris A., Monji A., et al. Antidepressants inhibit interferon-gamma-induced microglial production of IL-6 and nitric oxide. Exp Neurol 2007, 206(1):33-42.
135. Anway M.D., Folmer J., Wright W.W., Zirkin B.R. Isolation of Sertoli cells from adult rat testes: an approach to ex vivo studies of Sertoli cell function. Biol Reprod 2003, 68(3):996-1002.
136. Karl A.F., Griswold M.D. Sertoli cells of the testis: preparation of cell cultures and effects of retinoids. Methods Enzymol 1990, 190:71-75.
137. Valdes-Gonzalez R.A., Dorantes L.M., Garibay G.N., et al. Xenotransplantation of porcine neonatal islets of Langerhans and Sertoli cells: a 4-year study. Eur J Endocrinol 2005, 153(3):419-427.
138. Valdes-Gonzalez R., Dorantes L.M., Brancho-Blanchet E., Rodriguez-Venture A., White D.J.G. No evidence of procine endogenous retrovirus in patients with type 1 diabetes after long-term porcine islet xenotransplantation. J Med Virol 2010, 82(2):331-334.
139. Rahman T.M., Diakanov I., Selden C., Hodgson H. Co-transplantation of encapsulated HepG2 and rat Sertoli cells improves outcome in a thioacetamide induced rat model of acute hepatic failure. Transpl Int 2005, 18:1001-1009.
140. Zheng M.H., Lin H.L., Cui Y.L., Sun Q.F., Chen Y.P. Mixed microencapsulation of rat primary hepatocytes and Sertoli cells improves the metabolic function in a d-galactosamine and lipopolysaccharide-induced rat model of acute liver failure. Cytotherapy 2009, 11(3):326-329.
141. Rodriguez A.L., Willing A.E., Saporta S., Cameron D.F., Sanberg P.R. Effects of Sertoli cell transplants in a 3-nitropropionic acid model of early Huntington's disease: a preliminary study. Neurotox Res 2003, 5(6):443-450.
142. Emerich D.F. Sertoli cell grafts for Huntington's disease. An opinion. Neurotox Res 2004, 5(8):567.
143. Li Y., Xue W.J., Tian X.H., et al. Study on systemic immune tolerance induction in rat islet transplantation by intravenous infusion of Sertoli cells. Transplantation 2010, 89:1430-1437.
144. Mohr D.C., Goodkin D.E., Islar J., Hauser S.L., Genain C.P. Treatment of depression is associated with suppression of nonspecific and antigen-specific TH1 responses in multiple sclerosis. Arch Neurol 2001, 58:1081-1086.
145. Meroni S.B., Suburo A.M., Cigorraga S.B. Interleukin-1B regulates nitric oxide production and Y-glutamyl transpeptidase activity in Sertoli cells. J Androl 2000, 21(6):855-861.
146. Khovryakov A.V., Podrezova E.P., Kruglyakov P.P., et al. Involvement of NO synthase system in stress-mediated brain reactions. Neurosci Behav Physiol 2010, 40(3):333-337.
147. Mancuso C., Navarra P., Preziosi P. Roles of nitric oxide, carbon monoxide, and hydrogen sulfide in the regulation of the hypothalamic-pituitary-adrenal axis. J Neurochem 2010, 113(3):563-575.
148. Katoh-Semba R., Tsuzuki M., Miyazaki N., et al. Distribution and immunohistochemical localization of GDNF protein in selected neural and non-neural tissues of rats during development and changes in unilateral 6-hydroxydopamine lesions. Neurosci Res 2007, 59(3):277-287.
149. Yue F., Cui L., Johkura K., Ogiwara N., Sasaki K. Induction of midbrain dopaminergic neurons from primate embryonic stem cells by coculture with Sertoli cells. Stem cells 2006, 24(7):1695-1706.
150. Naughton C.K., Jain S., Strickland A.M., Gupta A., Milbrandt J. Glial cell-line derived neurotrophic factor-mediated RET signaling regulates spermatogonial stem cell fate. Biol Reprod 2006, 74(2):314-321.
151. Bronstein J.M., Tiwari-Woodruff S., Buznikov A.G., Stevens D.B. Involvement of OSP/claudin-11 in oligodendrocyte membrane interactions: role in biology and disease. J Neurosci Res 2000, 59(6):706-771.